Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Cytori Therapeutics, Inc. company was founded in 1996 and is headquartered in San Diego, California. Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors; and the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation. Cytori Therapeutics is conducting two clinical trials on adipose-derived stem and regenerative cells processed with the Celution 600 System in patients suffering from chronic myocardial ischemia and in heart attack patients. In addition, it develops and sells thin film bioresorbable implants in Japan. Further, the company operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Additionally, it has a joint venture with Olympus Corporation to develop and manufacture second generation devices based on its Celution system.

Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

Orchid Cellmark Inc. was founded in 1995 and is headquartered in Princeton, New Jersey. Orchid Cellmark Inc. operates as an international provider of identity DNA testing services for the forensic, immigration, and family relationships markets. The company has laboratories in the United States and the United Kingdom; and offers its services to police forces and other government entities. It also provides non-DNA forensic laboratory services. The company's forensic DNA testing is primarily used to confirm that a suspect committed a particular crime, to exonerate an innocent person, or to establish or maintain databases of individuals convicted of crimes; and family relationship DNA testing is used to establish whether two or more people are genetically related. Its DNA testing is used by individuals and employers in security applications to establish or store a person's genetic profile for identification purposes in the event of an emergency or accident. The company was formerly known as Orchid Biosciences Inc. and changed its name to Orchid Cellmark Inc. in June 2005.

Idera Pharmaceuticals, Inc. company was founded in 1989 and is based in Cambridge, Massachusetts. Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Ceragenix Pharmaceuticals was founded in 2002 is based in Denver, Colorado. Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders, and others. Its Ceragenin compounds are active against a range of gram positive and negative bacteria. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric barrier repair cream intended to create a skin barrier in premature infants and neonates.

China Sky One Medical, Inc. is engaged in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb based pharmaceutical and medicinal products. Its principal products are external use Traditional Chinese Herbal Remedies/Medicines (TCM). The Company is also an integrated manufacturer, marketer and distributor of external use Chinese medicine products sold primarily in China and through Chinese domestic pharmaceutical chains. The Company sells both its own manufactured products, as well as medicinal and pharmaceutical products manufactured by others in China. All of its business is conducted through its wholly owned subsidiary, American California Pharmaceutical Group, Inc. (ACPG) which, in turn, wholly owns Harbin Tian Di Ren Medical Science and Technology Company (TDR). On April 3, 2008, TDR completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.

Insys Therapeutics, Inc. company focuses on developing drugs for treating side effects of chemotherapy (such as nausea), as well as therapies for pain management and other central-nervous-system conditions. Its Dronabinol HG candidate, a generic capsule form of Marinol awaiting FDA approval, may treat chemotherapy-induced nausea and vomiting. The firm is also developing inhalation and room-temperature capsule and syrup forms of Dronabinol. In addition, its Fentanyl SL spray, delivered under the tongue for quick absorption, treats pain in cancer patients. All of the company's drug candidates are unique formulations of already-approved therapeutic ingredients.

Pharmaxis has an ax to grind with chronic respiratory and autoimmune diseases. The Australian company researches, develops, and markets therapeutic pharmaceutical products to combat these and other illnesses. Pharmaxis has received approval to market asthma treatment Aridol in select regions. The company has research and development programs for additional disease targets such as cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and pulmonary fibrosis. Pharmaxis acquired respiratory therapeutics developer TOPIGEN Pharmaceuticals in 2010, adding to Pharmaxis' roster of potential treatments for respiratory disorders including asthma and COPD.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.